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Abstract: Radiation pneumonitis (RP) is an important dose-limiting toxicity during thoracic 
radiotherapy. Previous investigations have shown that curcumin is used for the treatment of 
inflammatory conditions and cancer, suggesting that curcumin may prevent RP and sensitize 
cancer cells to irradiation. However, the clinical advancement of curcumin is limited by its poor 
water solubility and low bioavailability after oral administration. Here, a water-soluble lipo-
somal curcumin system was developed to investigate its prevention and sensitizing effects by an 
intravenous administration manner in mice models. The results showed that liposomal curcumin 
inhibited nuclear factor-κB pathway and downregulated inflammatory factors including tumor 
necrosis factor-α, interleukin (IL)-6, IL-8, and transforming growth factor-β induced by thoracic 
irradiation. Furthermore, the combined treatment with liposomal curcumin and radiotherapy 
increased intratumoral apoptosis and microvessel responses to irradiation in vivo. The signifi-
cantly enhanced inhibition of tumor growth also was observed in a murine lung carcinoma 
(LL/2) model. There were no obvious toxicities observed in mice. The current results indicate 
that liposomal curcumin can effectively mitigate RP, reduce the fibrosis of lung, and sensitize 
LL/2 cells to irradiation. This study also suggests that the systemic administration of liposomal 
curcumin is safe and deserves to be investigated for further clinical application.
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Introduction
Radiotherapy is one of the most important treatment modalities for many thoracic 
malignancies including lung cancer, breast cancer, lymphoma, thymoma, and esopha-
geal cancer. However, radiotherapy-induced lung toxicity frequently affects the out-
come of radiotherapy. Radiation pneumonitis (RP), which represents the acute phase 
of radiation-induced lung injury, is the major dose-limiting toxicity in radiotherapy for 
thoracic radiation. Despite recent improvements having been made on the delivery of 
radiotherapy, such as intensity-modulated radiotherapy and image-guided radiotherapy, 
clinically significant RP still develops in 13%–37% of patients receiving radical dose 
radiation therapy.1 RP-inducing acute clinical symptoms, mainly respiratory systemic 
symptoms, frequently result in radiotherapy failure. About 10%–15% patients develop 
severe lung toxicity after thoracic radiation.2 This is a significant problem and is con-
tributory to noncancer-related deaths in patients receiving radiotherapy.3,4 Another 
consequence of RP is lung fibrosis, which leads to shortness of breath, diminished 
quality of life, and reduced activities of daily living accordingly.
At the molecular level, RP is believed to be a consequence of a cascade of cytokine 
production.5 Nuclear factor (NF)-κB, a transcription factor, plays a central role in the 
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induction of cytokine expression in inflammatory response 
including the radiation-induced cascade of inflammatory 
responses and the further activation. Thus, inhibition of 
NF-κB is radioprotective for the lung and may be a synergetic 
strategy for cancer therapy.6–8
Curcumin, a NF-κB inhibitor, is used for the treat-
ment of inflammatory conditions and cancer, and can 
sensitize tumors to radiation including colorectal cancer, 
prostate cancer, and some squamous cell carcinoma.9–13 
Accumulating evidence also suggests that curcumin 
may be an ideal radioprotector for radiotherapy-induced 
lung injury. First, as a natural antioxidant, curcumin can 
capture and remove the free radicals caused by damage, 
and enhance the activity of superoxide dismutase.14 Sec-
ond, curcumin exerts multiple anti-inflammatory effects 
through the inhibition of the NF-κB pathway and decreases 
the release of inflammatory factors including monocyte 
chemotactic protein (MCP)-1, interleukin (IL)-1, and 
tumor necrosis factor (TNF)-α,10,15–18 Third, curcumin is 
believed to be a promising medicine for inhibiting, even 
correcting fibrosis.19,20 Therefore, curcumin is an ideal drug 
for preventing and treating RP, retarding fibrosis, and sen-
sitizing radiotherapy. However, the clinical advancement 
of curcumin has been limited by its poor water solubility, 
short biological half-life, and low bioavailability after oral 
administration.21–23 Development of intravenous adminis-
tration with curcumin is a promising approach to resolve 
these issues for further application.24
Materials and methods
Animals and cell lines
C57BL/6J mice were purchased from the West China 
Experimental Animal Center. Murine Lewis lung carcinoma cell 
line LL/2 and macrophage cell line RAW264.7 was purchased 
from American Type Culture Collection (Manassas, VA). 
Both cell lines were cultured in Dulbecco’s modified Eagle’s 
medium (Invitrogen, Carlsbad, CA), each supplemented with 
10% (vol/vol) fetal bovine serum (Invitrogen).
Preparation of curcumin-loaded liposomes 
(Lipo-cur) and empty liposomes
Lipo-cur were prepared by thin film method. Briefly, 18:1:1 
lecithin/cholesterol/curcumin (weight ratio) were dis-
solved in ethanol and evaporated to dryness under reduced 
pressure in a rotary evaporator. The dried lipid film was 
hydrated with phosphate-buffered solution (PBS) for 1 hour 
at 55°C. Then, the lipid suspension was extruded through 
0.4 µm and 0.1 µm pore size polycarbonate membranes on a 
nitrogen-driven Lipex lipid extruder (Northern Lipids Inc, 
Burnaby, BC, Canada). The empty liposomes were prepared 
as described above without addition of curcumin. The lipo-
somes were prepared in triplicate.
Characterization of Lipo-cur
Particle size and zeta potential of the Lipo-cur were deter-
mined by Malvern Nano-ZS 90 (Malvern Instruments, 
Worcestershire, UK). A transmission electron microscope 
(H-6009IV, Hitachi, Japan) was used to observe the morphol-
ogy of the Lipo-cur. The liposome dispersions were diluted 
five times with ultrapure water, dropped on copper grids with 
films and negatively stained with 2% (w/v) phosphotungstic 
acid, and dried at room temperature. Drug loading (DL) and 
encapsulation efficiency (EE) of Lipo-cur were determined as 
follows. Briefly, 10 mg of the lyophilized Lipo-cur was dis-
solved in 0.1 mL chloroform and then diluted with methanol. 
The amount of curcumin was determined by high perfor-
mance liquid chromatography (HPLC, Waters Alliance 2695, 
Waters, Milford, MA). Solvent delivery system was equipped 
with a column heater and a plus autosampler. Detection was 
carried out on a Waters 2996 detector. Chromatographic 
separations were performed on a reversed-phase C18 column 
(4.6 mm × 150 mm, 5 µm, Sunfire Analysis column), with 
the column temperature kept at 28°C. Methanol–0.3% acetic 
acid (80/20, v/v) was used as eluent at a flow rate of 1 mL 
min−1. Finally, the DL and EE of Lipo-cur were calculated 
according to the following equations:
 
DL =
Mc
Ml Mc +
× 100%  (1)
 
EE
Mc
M
=× 100%   (2)
where Mc, Ml, and M stand for the amount of encapsulated 
curcumin, the amount of lipids, and the amount of total 
curcumin used, respectively. All the experiments were 
performed in triplicate.
In-vivo toxicity of Lipo-cur
Lipo-cur (10 mg/kg) and normal saline (NS) were injected 
into C57BL/6J mice through the tail vein. The injections 
were continued for 7 days. The weight of mice was observed 
before the treatment and after 180 days; the survival of mice 
was also observed. Then the mice were sacrificed to obtain 
the liver, kidney, lung, spleen, brain, and heart for histo-
pathological analysis.
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Mice models and treatments
For the RP model, C57BL/6J mice were randomly assigned 
to receive hemi-lung radiation at a modified dose of 14 Gy 
as described previously.25 The hemi-lung radiation was per-
formed by placing pentobarbital-anesthetized mice individu-
ally in a plastic restrainer inside a 1.5 inch thick cerrobend 
shield that had a window (3.0 cm × 1.5 cm) exposing the 
right thoracic region to the radiation source.
Mice were kept at room temperature during radiation. 
The shield reduced the radiation dose to protected tissues by 
greater than 95%. Lipo-cur (5 mg/kg) and empty liposome 
was injected into each of the two groups of C57BL/6J mice 
through the tail vein on the second day after the RP model 
was established. The injections were continued for 7 days. 
Mice were sacrificed to obtain the blood plasma at 1, 2, 3, 4, 
5, and 6 weeks after radiation. In addition, the experiments 
were repeated; three mice per group were sacrificed to harvest 
lungs for histological analysis.
For the LL/2 Lewis lung carcinoma model, 5 × 105 
LL/2 Lewis lung carcinoma cells were subcutaneously 
injected in a total volume of 50 µL into the right leg of 
C57BL/6J mice (n = 6 per group). One group was treated 
with Lipo-cur by intravenous injection once a day for 
2 weeks; one group was treated with radiation therapy once 
every 3 days with 5 Gy 5 times (total dose = 25 Gy), one 
group was treated with the two modalities. One group was 
treated with empty liposome as a control. Tumors were 
measured. Tumor volume was calculated according to the 
formula: volume = width2 × length × 0.52.
Detection of chemokine production  
by enzyme-linked immunosorbent  
assay (ELISA)
IL-6, IL-8, IL-10, TNF-α, and transforming growth factor 
(TGF)-β cytokine concentration were measured by ELISA 
and expressed as pg/mL in plasma. Thawed plasma (200 µL) 
was used in the ELISA according to the manufacturer’s 
instructions. Optical absorbance was determined using an 
EXL-800 microplate reader.
Chemotaxis and chemokinesis assays
Murine macrophage-like (RAW264.7) cells were used to 
assess the effects of Lipo-cur to inhibit the activity of NF-κB. 
Migration of macrophage cell lines across a 10 pm thick 
Nucleopore® (Whatman plc, Maidstone, Kent, UK) polycar-
bonate filter containing 5 pm holes was measured in a 24-well 
chemotaxis chamber. The top wells contained 50,000 cells in 
minimum essential medium with 10% heat-inactivated fetal 
calf serum, and the bottom wells contained a 1:100 dilution of 
endotoxin-activated mouse serum in Roswell Park Memorial 
Institute 1640 medium. The cells were then incubated for 
4 hours at 37°C in an atmosphere of 5% CO2, 95% air.
Migrated cells were counted. AS605240 was used as a 
positive control as described previously.26 In most experi-
ments, less than 1% of the input cells migrated in the absence 
of attractant.
Electrophoretic mobility shift  
assays (EMSA)
NF-κB activation was analyzed by EMSA as follow. EMSA 
were performed by incubating 2.5 µg of nuclear extract in 12 
µL of binding buffer [5 mmol/L HEPES (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid), pH 7.9, 5 mmol/L MgCl2, 
50 mmol/L KCl, 0.5 mmol/L dithiothreitol, 0.4 mg/mL 
poly(dI-dC) (Pharmacia Biotech, Piscataway, NJ), 0.1 mg/mL 
sonicated double-stranded salmon sperm DNA, and 10% 
glycerol] for 10 minutes at room temperature. 32P end-
labeled 45-mer double-stranded NF-κB oligonucleotide 
from HIV-I long-terminal (5′- TTGTTACAAGGGACTTTC-
CGCTGGGGACTTTCCAGG- GAGG CGTGG-3′) was 
added and incubated for 30 minutes at 37°C, and the DNA– 
protein complex resolved in a 6.6% native polyacrylamide 
gel. A 32P-labeled oligonucleotide probe (30,000 cpm) 
was then added, and the reaction mixture was incubated for 
another 10 minutes at room temperature. For reactions involv-
ing competitive oligonucleotides, the unlabeled competitor, at 
100-fold molar excess, and the labeled probe were premixed 
before addition to the reaction mixture. For supershift assays, 
the reaction mixture minus the probe was incubated with 2 
µL of specific antibodies to NF-κB proteins for 30 minutes 
at room temperature. The 32P-labeled oligonucleotide probe 
was then added, and incubation was continued for 15 minutes. 
The samples were analyzed on 6% acrylamide gels. The gels 
were pre-electrophoresed at 12 V/cm for 1.5 hours at room 
temperature and 0.5 hours in a cold room, and the electropho-
resis was continued at the same voltage for another 2 hours at 
room temperature. Gel contents were transferred to Whatman 
chromatography paper (Markson Lab Sales, Hillsboro, OR), 
dried, and exposed to a PhosphorImage screen (Molecular 
Dynamics, Sunnyvale, CA) for 3 hours.
Immunohistochemistry  
and alginate-encapsulate tumor cell assay
To explore whether the antitumor immunity involved the 
inhibition of angiogenesis, detection of vessel density in 
tumor tissue and angiogenesis in vivo was done as described 
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previously.27 Frozen sections were used to determine 
vessel density with an anti-CD31 antibody. In addition, an 
alginate-encapsulate tumor cell assay was done. One group 
was treated with Lipo-cur by intravenous injection once 
a day for a week, and one group was treated with empty 
  liposome. After 12 days, mice were injected intravenously 
with 0.1 mL of a 100 mg/kg fluorescein isothiocyanate 
(FITC)-dextran (Sigma) solution. Alginate beads were 
photographed after being exposed surgically and then 
rapidly removed 20   minutes after FITC-dextran injection. 
The uptake of FITC-dextran was measured as described 
previously.28
Histopathological analysis
Hematoxylin-eosin (HE) staining and picric acid-Sirius red 
dyeing were performed. Mouse lungs were fixed by perfusion 
with 4% paraformaldehyde-PBS before routine processing 
and paraffin embedding. Sections (3 µm) were stained with 
HE for histological examination. The Ashcroft score was 
used for semiquantitative assessment of fibrotic changes.29,30 
The severity of fibrotic changes in each histological section 
of the lung was assessed as the mean score of severity from 
observed microscopic fields. Thirty fields in each section 
were analyzed. After examination of the whole fields of the 
section, the mean of the scores from all fields was considered 
the fibrotic score. To prevent bias of observation, grading 
was done in a blinded fashion by two observers.
Statistical analysis
SPSS Statistics (IBM Corporation, Somers, NY) software, 
version 11.5, was used for statistical analysis. The statistical 
significance of results in all of the experiments was deter-
mined by Student’s t-test and analysis of variance. Survival 
curves were compared by the log-rank test. The findings were 
regarded as significant if P , 0.05.
Results
Here, Lipo-cur with good water solubility was developed 
to explore its radioprotective effects for lung tissue, and 
sensitizing activity to lung cancer cells, in mice models with 
radiation. The study showed that a systemic administration 
of Lipo-cur could inhibit RP and sensitize lung carcinoma 
to radiation.
Preparation and characterization  
of Lipo-cur
Liposomes have been widely used carriers for lipophilic 
drugs.31,32 By preparing liposomes in this study, the 
concentration of curcumin in aqueous phase was significantly 
increased.
The Lipo-cur had a DL and an EE of 5.0 ± 0.2 and 
90.1 ± 1.7, respectively (n = 3). The liposomes were char-
acterized by photon correlation spectroscopy and exhibited 
a mean particle size of 114.9 ± 7.3 nm. The polydispersity 
index was 0.15 ± 0.04, indicating a very narrow particle size 
distribution. The liposomes were negatively charged, with a 
zeta potential of −2.62 ± 0.51 mV (n = 3). The particle size 
observed by transmission electron microscopy was consistent 
to that determined by particle size. The irregular surfaces of 
the spheres were probably ascribed to the dehydration process 
during sample preparation.
The appearance of curcumin aqueous solution, Lipo-cur, 
and curcumin ethanol solution are shown in Figure 1D. As 
curcumin is water-insoluble, its PBS solution was turbid. 
In contrast, the Lipo-cur solution was a translucent, yellow 
dispersion without sedimentation. The curcumin ethanol 
solution was clear and transparent.
Detection of toxicity
The mice treated with Lipo-cur were in particular investi-
gated for the potential long-term toxicity. No adverse con-
sequences were indicated in gross measures such as weight 
loss (Figure 2A), ruffling of fur, or life-span (Figure 2B). 
Furthermore, no pathologic changes of liver, kidney, lung, 
spleen, or brain were found by the microscopic examination 
(data not shown).
Effect of curcumin treatment on RP  
from single fraction X-ray radiation  
to the thorax in mice
Lungs were analyzed at 7, 14, 21, 28, 35, and 42 days for the 
onset of the pneumonitis reaction. Histopathologic changes 
were judged by two independent investigators in a blinded 
manner. These results revealed that radiation once with 
14 Gy lead to an increase in acute inflammatory infiltrate in 
the   interstitium. The mice from the control group developed 
pathognomonic alterations characteristic of pneumonitis, 
including alveolar wall thickness, interstitial edema, and 
interstitial and peribronchial inflammation after radiation. 
However, the lung tissue from the Lipo-cur-treated group only 
showed slight histopathologic changes during the 6 weeks 
(Figure 3A). The murine lung inflammation from the control 
group had further developed until progressive fibrosis of 
interstitium, while the systemic and repeated administra-
tion of Lipo-cur not only inhibited the onset of RP, but also 
retarded its process and sequelae (Figure 3B). The degree of 
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type I collagen deposition was confirmed by lung histology 
stained with Picric Acid-Sirius Red (Figure 4A). As antici-
pated, lung tissue specimens from the empty liposome 
group showed extensive Picric Acid-Sirius Red staining, 
indicating type I collagen deposition inside the alveolar wall. 
This suggested that the degree of lung fibrosis in the control 
group significantly increased compared with that in the Lipo-
cur-treated group (P , 0.01) (Figure 4B).
Cytokine plasma levels at the onset  
of RP mice
As a result of clearing apoptotic cells or as a direct response 
to radiation, the activation of macrophages may cause 
cytokine production, leading to lung injury.33 Here, the 
inhibitory effects of curcumin on activation of macrophages 
was   investigated. The results showed that curcumin not only 
inhibited the activity of NF-κB, but also blocked the migra-
tion of macrophages (Figure 5A and B). In vivo, plasma 
levels of both curcumin and NS group for IL-6, IL-8, TNF-α, 
and TGF-β cytokine concentration were measured at the first 
month of RP. The level of TGF-β from the Lipo-cur treatment 
group was lower than the NS group from the first week to the 
fourth week. Moreover, the level of TGF-β in the third week 
and fourth week was lower than that in the first week and 
second week in the Lipo-cur treatment group (Figure 5C). No 
difference of TNF-α and IL-8 was observed between the NS 
group and Lipo-cur group after the first week, but the level 
of TNF-α and IL-8 of the Lipo-cur group was lower than in 
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the NS group after the second week (Figure 5D and E). The 
level of IL-6 from the Lipo-cur treatment group was lower 
than the NS group from the first week to the fourth week; 
it reached its peak at the second week and then showed a 
gradual downward trend (Figure 5F).
Effects of curcumin and radiotherapy  
on tumor treatment
It has been reported that curcumin sensitizes human colorectal 
cancer xenografts in nude mice to gamma-radiation by target-
ing NF-κB-regulated gene products. The sensitizing effects 
of curcumin on murine lung cancer cells were investigated in 
LL/2 Lewis lung carcinoma cell model. There was significant 
inhibition of tumor growth in mice treated with curcumin 
plus radiotherapy. Although the antitumor effects were also 
detected in mice treated with curcumin and radiotherapy 
separately, the data suggest that the combined treatment of 
curcumin and radiotherapy can elicit an enhanced antitumor 
effect (Figure 6A and B). The further data from terminal 
deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) test also revealed curcumin plus radiotherapy 
induced significantly increased cellular apoptosis (Figure 6C 
and D). Therefore, the data suggest that Lipo-cur not only 
inhibit the process of RP, but also sensitize the antitumor 
effect of irradiation.
Inhibition of angiogenesis
A previous study indicates that irradiation induces endothelial 
cell apoptosis and resulting microvascular damage regulates 
tumor cell response to radiation.34 Accumulating evidence 
have been documented that curcumin inhibits angio-
genesis by targeting endothelial cells.35–37 In this study, 
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immunohistochemical staining (Figure 7A) of the tumor 
tissue from curcumin-treated mice with an anti-CD31 anti-
body showed significantly decreased microvessel density 
compared with that of the empty liposome group. Interest-
ingly, the microvessels were still obviously observed in 
tumor tissue from single irradiation-treated mice; however, 
both the microvessels and cancer cells showed morphologic 
abnormality, suggesting the damages and disfunction of these 
microvessels. The combined treatment with Lipo-cur plus 
radiotherapy resulted in significantly decreased microvessels 
(Figure 7A and B). In addition, inhibition of angiogenesis 
could also be detected in the alginate-encapsulate tumor 
cell assay (Figure 7C and D). New blood vessels in alginate 
beads from curcumin therapic mice were apparently sparse. 
Besides, FITC-dextran uptake was significantly decreased 
from Lipo-cur-treated mice. These findings further support 
that curcumin effectively inhibits tumor angiogenesis; it is a 
possible mechanism to sensitize LL/2 Lewis lung carcinoma 
cells to radiotherapy.
Discussion
Drug-loaded liposomes are expected to decrease the plasma 
clearance rate of the drug compared with free drug, and cor-
respondingly enhance the therapeutic efficacy.38   Therefore, 
developed in this work was a water-soluble Lipo-cur 
system.
RP is a common complication of thoracic radiother-
apy, and especially occurred in patients with lung cancer. 
Prevention and treatment of RP not only ameliorate patients’ 
clinical symptoms, but also improve the long-term survival 
quality. An optimal drug should be expected not only to 
prevent or treat RP, but also generate additional or synergic 
antitumor effects. This study suggests that the systemic 
administration of Lipo-cur can provide the double inhibi-
tory effects on both RP and cancer.
The lung tissues exposed to the ionizing radiation are 
likely to be affected not only by the radiation results on 
DNA but also by the activity of pro-inflammatory cytokines, 
which include IL-1α, IL-1β, TNF-α, IL-6, IL-8, and TGF-β. 
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of macrophages was detected first. (A) Curcumin inhibited the activity of NF-κB of macrophages. (B) Curcumin blocked the migration of macrophages (MCP-1, Cur: 
Cur+MCP-1, AS605240: AS605240+MCP-1). Then, the serum levels of both the Lipo and Lipo-cur group for IL-6, IL-8, TNF-α, and TGF-β cytokine concentration were 
measured at the first month of RP, mice in each group were bled for serum at the end of week 1, 2, 3, and 4 after being treated with Lipo or Lipo-cur. (C) The level of TGF-β 
from the Lipo-cur treatment group and the Lipo group. (D) The level of TNF-α from the Lipo-cur treatment group and the Lipo group. (E) The level of IL-8 from the Lipo-
cur treatment group and the Lipo group. (F) The level of IL-6 from the Lipo-cur treatment group and the Lipo group.
Notes: Data are mean ± standard error of the mean; *denotes P , 0.05 between groups.
Abbreviations:  Cur,  curcumin;  IL,  interleukin;  Lipo,  empty  liposome;  Lipo-cur,  liposomal  curcumin;  MCP,  monocyte  chemotactic  protein;  NF,  nuclear  factor;   
TGF, transforming growth factor; TNF, tumor necrosis factor.
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Although the target cell population and the underlying 
mechanism that initiates the process of RP in the lung remain 
unknown, it is accepted that a perpetual cascade of cytokine 
expression patterns are important for radiation-induced 
pneumonitis.5,39 The current working hypothesis suggests 
that complex alterations involve endothelial cells, pneumo-
cytes, macrophages, and other resident and transient cells.39,40 
Cytokines are produced not only in the normal lung tissue 
after radiation, but also overexpressed in tumor cells of non-
small cell lung cancer (NSCLC) specimens. For example, 
IL-6 is produced by lymphocytes, macrophages, fibroblasts, 
endothelial cells, bronchiolar epithelium, and some tumor 
cells.41,42 Notably, a recent study has suggested that tumor 
is the major source of circulating cytokines in patients with 
advanced NSCLC who have received RT,43 which supports 
the idea that tumor cells play more important roles in the 
process of RP. Therefore, the prevention and treatment of 
RP should not only aim to cascade signaling of cytokines, 
but also to reduce the release of cytokines from various cells, 
especially cancer cells.
A previous study has shown that ionizing radiation can 
directly activate NF-κB in various tumor cells and endothe-
lial cells,6 while the activation of NF-κB plays a central 
role in the regulation of multiple cellular processes such as 
inflammation, immune response, differentiation, prolifera-
tion, apoptosis, and carcinogenesis. In the process of RP, 
NF-κB, as an important transcription factor, plays double 
roles both in producing and signaling of pro-inflammatory 
cytokines.7,44 Pro-inflammatory genes can be expressed 
in various cells including T cells, macrophages, endothe-
lial cells, and especially tumor cells, while inhibition of 
NF-κB results in a decrease of the cytokines in these cells.45 
Therefore, decreasing the secretion of cytokines from these 
cytokine-producing cells and downregulating cytokine sig-
naling in possible target cells are necessary to effectively 
inhibit the process of RP. Accumulating evidence has shown 
that curcumin inhibits the activity of NF-κB in various 
cells.10,45,46 The macrophage plays multiple roles in tissue 
injury and is involved in production and signal transduction 
of pro-inflammatory cytokines through the NF-κB-dependent 
way.34,47,48 The current study showed that curcumin effectively 
inhibits activity of murine macrophage-like (RAW264.7) 
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Figure 6 Lipo-cur sensitizes cancer cells to RT. (A and B) C57BL/6J mouse tumor 
model was established by subcutaneous injection with 5 × 105 LL/2 cells. Mice 
(six mice in each group) were treated with 100 µg of Lipo-cur (▲) (intravenous 
route), RT (◊), Lipo-cur (intravenous route) and RT (■), or Lipo solution alone (●). 
Significant difference was found in tumor volume (*denotes P , 0.05) between RT-
curcumin group and those two methods alone. Points, mean (n = 8); bars, standard 
deviation. (C and D) Apoptosis of lung cancer cells was detected using TUNEL 
analysis. The percentage of apoptosis was determined by counting the number of 
apoptotic cells and dividing by the total number of cells in the field (five high power 
fields per slide).
Notes:  The  combined  treatment  with  Lipo-cur  and  RT  resulted  in  significantly 
increased  apoptosis  compared  with  that  of  other  groups  (*denotes  P  ,  0.05, 
**denotes P , 0.01); bars, standard deviation; columns, mean.
Abbreviations: Lipo, empty liposome; Lipo-cur, liposomal curcumin; RT, radiotherapy; 
TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.
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Figure 7 Inhibition of angiogenesis within tumors. (A and B) Frozen sections of 
tumor tissue were tested by immunohistochemical analysis of anti-CD31 antibody, 
and vascular density was quantified by counting the number of microvessels per 
high power field (×400). Vessel density of tumor tissues from combined treatment 
with Lipo-cur and RT indicated a decrease compared with the phosphate-buffered 
saline group (five high power fields per slide). (C and D) Alginate beads containing 
1 × 105 LL/2 cells per bead were then implanted subcutaneously into the backs of 
mice. One group was treated with curcumin by intravenous injection once a day 
for 1 week, and one group was treated with normal saline. Beads were surgically 
removed 12 days later, and FITC-dextran was quantified. FITC-dextran uptake of 
beads from curcumin-treated mice showed a significant decrease compared with 
normal saline group.
Notes: *Denotes P , 0.05; **denotes P , 0.01; columns, mean; bars, standard 
deviations.
Abbreviations: FITC, fluorescein isothiocyanate; Lipo, empty liposome; Lipo-cur, 
liposomal curcumin; RT, radiotherapy.
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cells, which further proved that curcumin could mitigate RP 
through inhibition of the NF-κB pathway.
As we know, the process of RP involves a complicated 
signal network of cytokines and chemokines. The biological 
effects of TNF-α are achieved by activation of signaling cas-
cades that elicit a pro-inflammatory gene expression program, 
leading to an increased vascular permeability, and a hallmark 
of the inflammatory response.49 IL-6 plays important roles 
in the regulation of immune response and inflammation, 
and can be used as a predictor of RP.50,51 IL-8 not only is a 
pro-inflammatory cytokine but also stimulates collagen syn-
thesis and matrix production, even angiogenesis.52,53 TGF-β 
expression in response to radiation plays an important role in 
postradiation lung injury, which results in collagen deposition, 
increased alveolar wall thickness, and endothelial damage.54,55 
In this study, the systemic treatment with Lipo-cur resulted in 
the significant decreased sera levels of TNF-α, IL-6, IL8, and 
TGF-β, which further relieved the inflammation and fibrosis 
of the irradiated lung. Therefore, the present study documents 
that curcumin can be used as a protector for RP.
Accumulating evidence has shown that curcumin 
sensitizes cancer cells to radiation and chemotherapy by 
targeting the NF-κB pathway.11,38 Moreover, curcumin has 
shown to inhibit the functions of endothelial cells by target-
ing the NF-κB/Akt pathway.56,57 It is accepted worldwide 
that angiogenesis plays a pivotal role in tumor growth and 
metastases, and radiation-inducing endothelial cell apoptosis 
regulates tumor response to radiotherapy.35 The results of this 
present study further support that the systemic administra-
tion of Lipo-cur may sensitize the murine lung cancer cells 
to radiation by inhibiting angiogenesis and show systemic 
antitumor effects. Therefore, compared with other radiation 
protectors and therapeutic drugs of RP, such as amifostine 
and dexamethasone, curcumin may play another irradiation 
sensitizer role in further clinical application for the patients 
receiving thoracic radiotherapy.
A Phase I study which involved curcumin-dose escala-
tion evaluation found no trace of curcumin at oral doses of 
500–8000 mg/d, and only trace amounts in a minority of 
patients at 10–12 g of curcumin intake per day.22 The therapeu-
tic effects of curcumin are mainly limited by oral administration 
due to the reduced bioavailability.58,59 A variety of approaches 
are being pursued to overcome these limitations, which include 
synthesis of curcumin analogues, the use of adjuvants (eg, 
piperine), and the development of improved delivery platforms 
for the parental compound, including liposomal, nanoparticu-
lated, and phospholipid complex formulations of curcumin.23 
In this present study, the   injectable   Lipo-cur was prepared and 
a systemic administration   performed. The effects of Lipo-cur 
were confirmed effectively; moreover, there were no observed 
side effects in vivo.
In summary, this study indicates that Lipo-cur may be 
an optimal radiation protector against RP and sensitizer for 
radiation therapy. The systemic administration of Lipo-cur 
for patients who receive thoracic radiation should be inves-
tigated in further clinical trials.
Conclusion
In this study, a water-soluble Lipo-cur system was success-
fully developed. The results indicate that Lipo-cur can effec-
tively mitigate RP, reduce the fibrosis of lung, and sensitize 
LL/2 cells to irradiation. This study also suggests that the 
systemic administration of Lipo-cur is safe and deserves to 
be investigated for further clinical application.
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